WHO ICTRP trial
Blood-brain-barrier disruption therapy in primary central nervous system…
EUCTR2014-005015-16-FI · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2014-005015-16-FI |
|---|---|
| Public title | Blood-brain-barrier disruption therapy in primary central nervous system lymphoma |
| Scientific title | Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma |
| Primary sponsor | Oulu University Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Finland |
| Conditions | Primary centra nervous system lymphoma;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: rituximabi Pharmaceutical Form: Solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Product Name: carboplatin Pharmaceutical Form: Solution for infusion Other descriptive name: CARBOPLATIN Product… |
| Registration date | Dec 22, 2016 |
| Target size | 44 |
| Secondary IDs | BBBD-01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: